These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

610 related items for PubMed ID: 11437399

  • 1. CAG and GGC repeat polymorphisms in the androgen receptor gene and breast cancer susceptibility in BRCA1/2 carriers and non-carriers.
    Kadouri L, Easton DF, Edwards S, Hubert A, Kote-Jarai Z, Glaser B, Durocher F, Abeliovich D, Peretz T, Eeles RA.
    Br J Cancer; 2001 Jul 06; 85(1):36-40. PubMed ID: 11437399
    [Abstract] [Full Text] [Related]

  • 2. Androgen receptor (CAG)n and (GGC)n polymorphisms and breast cancer risk in a population-based case-control study of young women.
    Suter NM, Malone KE, Daling JR, Doody DR, Ostrander EA.
    Cancer Epidemiol Biomarkers Prev; 2003 Feb 06; 12(2):127-35. PubMed ID: 12582022
    [Abstract] [Full Text] [Related]

  • 3. Polyglutamine repeat length in the AIB1 gene modifies breast cancer susceptibility in BRCA1 carriers.
    Kadouri L, Kote-Jarai Z, Easton DF, Hubert A, Hamoudi R, Glaser B, Abeliovich D, Peretz T, Eeles RA.
    Int J Cancer; 2004 Jan 20; 108(3):399-403. PubMed ID: 14648706
    [Abstract] [Full Text] [Related]

  • 4. The androgen receptor and genetic susceptibility to ovarian cancer: results from a case series.
    Levine DA, Boyd J.
    Cancer Res; 2001 Feb 01; 61(3):908-11. PubMed ID: 11221880
    [Abstract] [Full Text] [Related]

  • 5. Population-based estimate of the average age-specific cumulative risk of breast cancer for a defined set of protein-truncating mutations in BRCA1 and BRCA2. Australian Breast Cancer Family Study.
    Hopper JL, Southey MC, Dite GS, Jolley DJ, Giles GG, McCredie MR, Easton DF, Venter DJ.
    Cancer Epidemiol Biomarkers Prev; 1999 Sep 01; 8(9):741-7. PubMed ID: 10498392
    [Abstract] [Full Text] [Related]

  • 6. The lifetime risks of breast cancer in Ashkenazi Jewish carriers of BRCA1 and BRCA2 mutations.
    Satagopan JM, Offit K, Foulkes W, Robson ME, Wacholder S, Eng CM, Karp SE, Begg CB.
    Cancer Epidemiol Biomarkers Prev; 2001 May 01; 10(5):467-73. PubMed ID: 11352856
    [Abstract] [Full Text] [Related]

  • 7. Ovarian cancer risk in Ashkenazi Jewish carriers of BRCA1 and BRCA2 mutations.
    Satagopan JM, Boyd J, Kauff ND, Robson M, Scheuer L, Narod S, Offit K.
    Clin Cancer Res; 2002 Dec 01; 8(12):3776-81. PubMed ID: 12473589
    [Abstract] [Full Text] [Related]

  • 8. Increased risk of breast cancer in women bearing a combination of large CAG and GGN repeats in the exon 1 of the androgen receptor gene.
    González A, Javier Dorta F, Rodriguez G, Brito B, Rodríguez MA, Cabrera A, Díaz-Chico JC, Reyes R, Aguirre-Jaime A, Nicolás Díaz-Chico B.
    Eur J Cancer; 2007 Nov 01; 43(16):2373-80. PubMed ID: 17728127
    [Abstract] [Full Text] [Related]

  • 9. Androgen receptor CAG repeat length in Jewish Israeli women who are BRCA1/2 mutation carriers: association with breast/ovarian cancer phenotype.
    Dagan E, Friedman E, Paperna T, Carmi N, Gershoni-Baruch R.
    Eur J Hum Genet; 2002 Nov 01; 10(11):724-8. PubMed ID: 12404104
    [Abstract] [Full Text] [Related]

  • 10. Mutational analyses of BRCA1 and BRCA2 in Ashkenazi and non-Ashkenazi Jewish women with familial breast and ovarian cancer.
    Shiri-Sverdlov R, Oefner P, Green L, Baruch RG, Wagner T, Kruglikova A, Haitchick S, Hofstra RM, Papa MZ, Mulder I, Rizel S, Bar Sade RB, Dagan E, Abdeen Z, Goldman B, Friedman E.
    Hum Mutat; 2000 Dec 01; 16(6):491-501. PubMed ID: 11102978
    [Abstract] [Full Text] [Related]

  • 11. A single nucleotide polymorphism in the 5' untranslated region of RAD51 and risk of cancer among BRCA1/2 mutation carriers.
    Wang WW, Spurdle AB, Kolachana P, Bove B, Modan B, Ebbers SM, Suthers G, Tucker MA, Kaufman DJ, Doody MM, Tarone RE, Daly M, Levavi H, Pierce H, Chetrit A, Yechezkel GH, Chenevix-Trench G, Offit K, Godwin AK, Struewing JP.
    Cancer Epidemiol Biomarkers Prev; 2001 Sep 01; 10(9):955-60. PubMed ID: 11535547
    [Abstract] [Full Text] [Related]

  • 12. Cancer risks in carriers of the BRCA1/2 Ashkenazi founder mutations.
    Kadouri L, Hubert A, Rotenberg Y, Hamburger T, Sagi M, Nechushtan C, Abeliovich D, Peretz T.
    J Med Genet; 2007 Jul 01; 44(7):467-71. PubMed ID: 17307836
    [Abstract] [Full Text] [Related]

  • 13. Ashkenazi Jewish population frequencies for common mutations in BRCA1 and BRCA2.
    Roa BB, Boyd AA, Volcik K, Richards CS.
    Nat Genet; 1996 Oct 01; 14(2):185-7. PubMed ID: 8841191
    [Abstract] [Full Text] [Related]

  • 14. The androgen receptor CAG repeat polymorphism and risk of breast cancer in the Nurses' Health Study.
    Haiman CA, Brown M, Hankinson SE, Spiegelman D, Colditz GA, Willett WC, Kantoff PW, Hunter DJ.
    Cancer Res; 2002 Feb 15; 62(4):1045-9. PubMed ID: 11861380
    [Abstract] [Full Text] [Related]

  • 15. Testosterone levels in relation to oral contraceptive use and the androgen receptor CAG and GGC length polymorphisms in healthy young women.
    Hietala M, Sandberg T, Borg A, Olsson H, Jernström H.
    Hum Reprod; 2007 Jan 15; 22(1):83-91. PubMed ID: 16920725
    [Abstract] [Full Text] [Related]

  • 16. Polymorphic CAG and GGN repeat lengths in the androgen receptor gene and prostate cancer risk: a population-based case-control study in China.
    Hsing AW, Gao YT, Wu G, Wang X, Deng J, Chen YL, Sesterhenn IA, Mostofi FK, Benichou J, Chang C.
    Cancer Res; 2000 Sep 15; 60(18):5111-6. PubMed ID: 11016637
    [Abstract] [Full Text] [Related]

  • 17. Skewed X chromosome inactivation and breast and ovarian cancer status: evidence for X-linked modifiers of BRCA1.
    Lose F, Duffy DL, Kay GF, Kedda MA, Spurdle AB, Kathleen Cuningham Foundation Consortium for Research into Familial Breast Cancer, Australian Ovarian Cancer Study Management Group.
    J Natl Cancer Inst; 2008 Nov 05; 100(21):1519-29. PubMed ID: 18957670
    [Abstract] [Full Text] [Related]

  • 18. The rate of the founder Jewish mutations in BRCA1 and BRCA2 in prostate cancer patients in Israel.
    Vazina A, Baniel J, Yaacobi Y, Shtriker A, Engelstein D, Leibovitz I, Zehavi M, Sidi AA, Ramon Y, Tischler T, Livne PM, Friedman E.
    Br J Cancer; 2000 Aug 05; 83(4):463-6. PubMed ID: 10945492
    [Abstract] [Full Text] [Related]

  • 19. The carrier frequency of the BRCA2 6174delT mutation among Ashkenazi Jewish individuals is approximately 1%.
    Oddoux C, Struewing JP, Clayton CM, Neuhausen S, Brody LC, Kaback M, Haas B, Norton L, Borgen P, Jhanwar S, Goldgar D, Ostrer H, Offit K.
    Nat Genet; 1996 Oct 05; 14(2):188-90. PubMed ID: 8841192
    [Abstract] [Full Text] [Related]

  • 20. Intron variants of the p53 gene are associated with increased risk for ovarian cancer but not in carriers of BRCA1 or BRCA2 germline mutations.
    Wang-Gohrke S, Weikel W, Risch H, Vesprini D, Abrahamson J, Lerman C, Godwin A, Moslehi R, Olipade O, Brunet JS, Stickeler E, Kieback DG, Kreienberg R, Weber B, Narod SA, Runnebaum IB.
    Br J Cancer; 1999 Sep 05; 81(1):179-83. PubMed ID: 10487631
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 31.